NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Peking University
Merck Sharp & Dohme LLC
Incyte Corporation
Verastem, Inc.
AstraZeneca
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's